29.43
+0.43(+1.48%)
Currency In USD
| Previous Close | 29 |
| Open | 29.95 |
| Day High | 30.4 |
| Day Low | 29 |
| 52-Week High | 65.8 |
| 52-Week Low | 2.62 |
| Volume | 331,099 |
| Average Volume | 335,942 |
| Market Cap | 186.41M |
| PE | -0.11 |
| EPS | -273.6 |
| Moving Average 50 Days | 36.59 |
| Moving Average 200 Days | 25.07 |
| Change | 0.43 |
If you invested $1000 in Vor Biopharma Inc. (VOR) since IPO date, it would be worth $784.8 as of October 20, 2025 at a share price of $29.43. Whereas If you bought $1000 worth of Vor Biopharma Inc. (VOR) shares 3 years ago, it would be worth $7,624.35 as of October 20, 2025 at a share price of $29.43.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Vor Bio Announces Late-Breaking Oral Presentation of China Phase 3 IgA Nephropathy Clinical Study at American Society of Nephrology’s Kidney Week 2025
GlobeNewswire Inc.
Oct 17, 2025 12:00 PM GMT
CAMBRIDGE, Mass., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that clinical data from Stage A of a Phase 3 study in China sponsor
Vor Bio Announces Publication of China Phase 3 Study of Telitacicept in Systemic Lupus Erythematosus in The New England Journal of Medicine
GlobeNewswire Inc.
Oct 16, 2025 12:00 PM GMT
Trial met primary endpoint achieving statistically significant improvement in disease activity, with 67.1% of patients responding with telitacicept versus 32.7% with placebo Dual inhibition of BAFF and APRIL validated as a transformative B-cell appr
Telitacicept Demonstrates Clinically Meaningful and Statistically Significant Impact on ESSDAI Compared to Placebo in Late-Breaking China Phase 3 Results in Primary Sjögren’s Disease at ACR 2025
GlobeNewswire Inc.
Oct 14, 2025 12:00 PM GMT
Telitacicept met primary and all secondary endpoints, demonstrating clinically meaningful improvements in disease activity versus placebo ~71.8% of patients receiving telitacicept 160mg achieved ≥3-point ESSDAI (EULAR Sjögren’s Syndrome Disease Activ